KDR and neoplasm: Administration of VEGFR2 extracellular domain-expressing T4 recombinant phages inhibits VEGF-mediated tumor angiogenesis by binding specifically to vascular endothelial growth factor (VEGF), thus inhibiting downstream signaling pathways and suppressing tumor growth and microvascular density in vivo [166].